These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 30774305)

  • 1. A real-life experience of sorafenib treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis at Cathay General Hospital, 2007-2015.
    Huang CC; Chen HY; Chang RH; Liao PA; Lien HH; Hung CS; Yang SS; Hu JT
    Drug Des Devel Ther; 2019; 13():397-404. PubMed ID: 30774305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.
    Yada M; Masumoto A; Motomura K; Tajiri H; Morita Y; Suzuki H; Senju T; Koyanagi T
    World J Gastroenterol; 2014 Sep; 20(35):12581-7. PubMed ID: 25253961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice.
    Lee IC; Chen YT; Chao Y; Huo TI; Li CP; Su CW; Lin HC; Lee FY; Huang YH
    Medicine (Baltimore); 2015 Apr; 94(14):e688. PubMed ID: 25860213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib.
    Hong YM; Yoon KT; Hwang TH; Heo J; Woo HY; Cho M
    Eur J Gastroenterol Hepatol; 2019 Oct; 31(10):1250-1255. PubMed ID: 30925530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea.
    Lee MJ; Chang SW; Kim JH; Lee YS; Cho SB; Seo YS; Yim HJ; Hwang SY; Lee HW; Chang Y; Jang JY
    Invest New Drugs; 2021 Feb; 39(1):260-268. PubMed ID: 32749658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.
    Ni JY; Kong J; Sun HL; Chen YT; Luo JH; Wang WD; Chen D; Jiang XY; Xu LF
    Acad Radiol; 2018 Apr; 25(4):423-429. PubMed ID: 29198946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib treatment on Chinese patients with advanced hepatocellular carcinoma: A study on prognostic factors of the viral and tumor status.
    Lee SW; Lee TY; Peng YC; Yang SS; Yeh HZ; Chang CS
    Medicine (Baltimore); 2019 Nov; 98(44):e17692. PubMed ID: 31689794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
    Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
    Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma.
    Jouve JL; Lecomte T; Bouché O; Barbier E; Khemissa Akouz F; Riachi G; Nguyen Khac E; Ollivier-Hourmand I; Debette-Gratien M; Faroux R; Villing AL; Vergniol J; Ramee JF; Bronowicki JP; Seitz JF; Legoux JL; Denis J; Manfredi S; Phelip JM;
    J Hepatol; 2019 Sep; 71(3):516-522. PubMed ID: 31125576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are we SHARP enough? The importance of adequate patient selection in sorafenib treatment for hepatocellular carcinoma.
    Labeur TA; Ten Cate DWG; Bart Takkenberg R; Azahaf H; van Oijen MGH; van Delden OM; de Man RA; van Vugt JLA; IJzermans JNM; Eskens FALM; Klümpen HJ
    Acta Oncol; 2018 Nov; 57(11):1467-1474. PubMed ID: 29943624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.
    Lee SH; Song IH; Noh R; Kang HY; Kim SB; Ko SY; Lee ES; Kim SH; Lee BS; Kim AN; Chae HB; Kim HS; Lee TH; Kang YW; Lee JD; Lee HY
    BMC Cancer; 2015 Apr; 15():236. PubMed ID: 25885683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis.
    McNamara MG; Slagter AE; Nuttall C; Frizziero M; Pihlak R; Lamarca A; Tariq N; Valle JW; Hubner RA; Knox JJ; Amir E
    Eur J Cancer; 2018 Dec; 105():1-9. PubMed ID: 30384012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma.
    Lin SM; Lu SN; Chen PT; Jeng LB; Chen SC; Hu CT; Yang SS; Le Berre MA; Liu X; Mitchell DY; Prins K; Grevel J; Peña CA; Meinhardt G
    Hepatol Int; 2017 Mar; 11(2):199-208. PubMed ID: 27909950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
    Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU
    J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.
    Inghilesi AL; Gallori D; Antonuzzo L; Forte P; Tomcikova D; Arena U; Colagrande S; Pradella S; Fani B; Gianni E; Boni L; Laffi G; Di Costanzo F; Marra F
    World J Gastroenterol; 2014 Jan; 20(3):786-94. PubMed ID: 24574751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study.
    Lee S; Kim BK; Kim SU; Park SY; Kim JK; Lee HW; Park JY; Kim DY; Ahn SH; Tak WY; Kweon YO; Lee JI; Lee KS; Kim HJ; Han KH
    J Gastroenterol Hepatol; 2014; 29(7):1463-9. PubMed ID: 25273508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic effects of regorafenib after sorafenib monotherapy with advanced hepatocellular carcinoma including Child-Pugh classification B: A retrospective observational study.
    Komiyama S; Numata K; Ogushi K; Moriya S; Fukuda H; Chuma M; Maeda S
    Medicine (Baltimore); 2020 Jul; 99(29):e21191. PubMed ID: 32702881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Lyu N; Kong Y; Mu L; Lin Y; Li J; Liu Y; Zhang Z; Zheng L; Deng H; Li S; Xie Q; Guo R; Shi M; Xu L; Cai X; Wu P; Zhao M
    J Hepatol; 2018 Jul; 69(1):60-69. PubMed ID: 29471013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower Serum Sodium Levels Are Associated with the Therapeutic Effect of Sorafenib on Hepatocellular Carcinoma.
    Kegasawa T; Sakamori R; Maesaka K; Yamada R; Tahata Y; Urabe A; Kodama T; Hikita H; Imanaka K; Ohkawa K; Hiramatsu N; Oshita M; Yamada Y; Inada M; Yakushijin T; Imai Y; Tatsumi T; Takehara T
    Dig Dis Sci; 2021 May; 66(5):1720-1729. PubMed ID: 32556820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
    Vogel A; Qin S; Kudo M; Su Y; Hudgens S; Yamashita T; Yoon JH; Fartoux L; Simon K; López C; Sung M; Mody K; Ohtsuka T; Tamai T; Bennett L; Meier G; Breder V
    Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):649-658. PubMed ID: 34087115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.